- Home
- NBXG vs SNDX Comparison
NBXG vs SNDX Comparison
Compare NBXG & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- SNDX
- Stock Information
- Founded
- NBXG 2021
- SNDX 2005
- Country
- NBXG United States
- SNDX United States
- Employees
- NBXG N/A
- SNDX N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- NBXG Finance
- SNDX Health Care
- Exchange
- NBXG Nasdaq
- SNDX Nasdaq
- Market Cap
- NBXG 1.1B
- SNDX 1.1B
- IPO Year
- NBXG N/A
- SNDX 2016
- Fundamental
- Price
- NBXG $14.45
- SNDX $9.60
- Analyst Decision
- NBXG
- SNDX Strong Buy
- Analyst Count
- NBXG 0
- SNDX 11
- Target Price
- NBXG N/A
- SNDX $34.18
- AVG Volume (30 Days)
- NBXG 243.7K
- SNDX 2.0M
- Earning Date
- NBXG 01-01-0001
- SNDX 07-31-2025
- Dividend Yield
- NBXG 10.25%
- SNDX N/A
- EPS Growth
- NBXG N/A
- SNDX N/A
- EPS
- NBXG N/A
- SNDX N/A
- Revenue
- NBXG N/A
- SNDX $43,722,000.00
- Revenue This Year
- NBXG N/A
- SNDX $426.77
- Revenue Next Year
- NBXG N/A
- SNDX $98.31
- P/E Ratio
- NBXG N/A
- SNDX N/A
- Revenue Growth
- NBXG N/A
- SNDX N/A
- 52 Week Low
- NBXG $9.31
- SNDX $8.58
- 52 Week High
- NBXG $12.23
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- NBXG 67.32
- SNDX 48.99
- Support Level
- NBXG $14.42
- SNDX $8.59
- Resistance Level
- NBXG $14.63
- SNDX $10.01
- Average True Range (ATR)
- NBXG 0.19
- SNDX 0.54
- MACD
- NBXG -0.03
- SNDX 0.10
- Stochastic Oscillator
- NBXG 78.26
- SNDX 71.48
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.